Correlation between omental TNF-α protein and plasma PAI-1 in obesity subjects

International Journal of Cardiology

Volumn 128, Issue 3, 2008, Pages 399-405

  Cao, Yan Li ^a   Wang, Yu Xia ^a   Wang, Di Fei ^a   Meng, Xin ^a   Zhang, Jin ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

Author keywords

Obesity; Omentum; Plasminogen activator inhibitor 1; Tumor necrosis factor alpha; Vascular diseases

Indexed keywords

GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; CLINICAL ARTICLE; CORRELATION ANALYSIS; FEMALE; HUMAN; INTRAABDOMINAL FAT; MALE; OBESITY; PERITONEAL BIOPSY; PRIORITY JOURNAL; SUBCUTANEOUS FAT;

ADULT; FEMALE; HUMANS; INTRA-ABDOMINAL FAT; MALE; MIDDLE AGED; OBESITY; OMENTUM; PLASMINOGEN ACTIVATOR INHIBITOR 1; THINNESS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 48149107176     PISSN: 01675273     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijcard.2007.05.033     Document Type: Article

References (32)

1. Cancello R., Tordjman J., Poitou C., et al. Increased infiltration of macrophages in omental adipose tissue is associated with marked hepatic lesions in morbid human obesity. Diabetes 55 (2006) 1554-1561
2. Matsuzawa Y. Therapy insight: adipocytokines in metabolic syndrome and related cardiovascular disease. Nat Clin Pract Cardiovasc Med 3 (2006) 5-42
3. Fried S.K., Lavau M., and Pi-Sunyer F.X. Variations of glucose metabolism by fat cells from three adipose depots of the rat. Metabolism 31 (1982) 76-883
4. Bruun J.M., Lihn A.S., Madan A.K., et al. Higher production of IL-8 in visceral vs. subcutaneous adipose tissue. Implication of nonadipose cells in adipose tissue. Am J Physiol Endocrinol Metab 286 (2004) E8-E13
5. Atzmon G., Yang X.M., Muzumdar R., Ma X.H., Gabriely I., and Barzilai N. Differential gene expression between visceral and subcutaneous fat depots. Horm Metab Res 34 (2002) 622-628
6. Rahmouni K., Mark A.L., Haynes W.G., and Sigmund C.D. Adipose depot-specific modulation of angiotensinogen gene expression in diet-induced obesity. Am J Physiol Endocrinol Metab 286 (2004) E891-E895
7. Hotamisligil G.S., Shargil N.S., and Spieglman B.M. Adipose expression of tumor necrosis factor-α direct role in obesity-linked insulin resistance. Science 259 (1993) 87-91
8. Hotamisligil G.S., Arner P., Caro J.F., Atkinson R.L., and Spiegelman B.M. Increased adipose tissue expression of tumor necrosis factor-alpha in human obesity and insulin resistance. J Clin Invest 95 (1995) 2409-2415
9. Ronti T., Lupattelli G., and Mannarino E. The endocrine function of adipose tissue: an update. Clin Endocrinol 64 (2006) 355-365
10. Martens F.M.A.C., Rabelink T.J., op 't Roodt J., de Koning E.J.P., and Visseren F.L.J. Tumor necrosis factor-alpha induces endothelial dysfunction in diabetic adults, an effect reversible by the PPAR-gamma agonist pioglitazone. Eur Heart J 27 (2006) 1605-1609
11. Paquot N., and Tappy L. Adipocytokines: link between obesity, type 2 diabetes and atherosclerosis. Rev Med Liege 60 (2005) 369-373
12. Sobel B.E. Increased plasminogen activator inhibitor-1 and vasculopathy. A reconcilable paradox. Circulation 99 (1999) 2496-2498
13. Birgel M., Gottschling-Zeller H., Rohrig K., and Hauner H. Role of cytokines in the regulation of plasminogen activator inhibitor-1 expression and secretion in newly differentiated subcutaneous human adipocytes. Arterioscler Thromb Vasc Biol 20 (2000) 1682-1687
14. Thogersen A.M., Jansson J.H., Boman K., et al. High plasminogen activator inhibitor and tissue plasminogen activator levels in plasma precede a first acute myocardial infarction in both men and women: evidence for the fibrinolytic system as an independent primary risk factor. Circulation 98 (1998) 2241-2247
15. He G., Pedersen S.B., Bruun J.M., Lihn A.S., Jensen P.F., and Richelsen B. Differences in plasminogen activator inhibitor 1 in subcutaneous versus omental adipose tissue in non-obese and obese subjects. Horm Metab Res 35 (2003) 178-182
16. Chen C.M., Kong L.Z., Wen Z.M., et al. The guidelines for prevention and control of overweight and obesity in Chinese adults. Biomed Environ Sci 17 (2004) 1-36
17. Matthews D.R., Hosker J.P., Rudenski A.S., Naylor B.A., Treacher D.F., and Turner R.C. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28 (1985) 412-419
18. Winkler G., Kiss S., Keszthelyi L., et al. Expression of tumor necrosis factor (TNF)-alpha protein in the subcutaneous and visceral adipose tissue in correlation with adipocytes cell volume, serum TNF-alpha, soluble serum TNF-receptor-2 concentrations and C-peptide level. Eur J Endocrinol 149 (2003) 129-135
19. Juhan-Vague I., Pyke S.D., Alessi M.C., Jespersen J., Haverkate F., and Thompson S.G. Fibrinolytic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris: ECAT Study Group: European Concerted Action on Thrombosis and Disabilities. Circulation 94 (1996) 2057-2063
20. Alessi M.C., Bastelica D., Morange P.E., et al. Plasminogen activator inhibitor-1, transforming growth factor beta 1 and body mass index are closely associated in human adipose tissue during morbid obesity. Diabetes 49 (2000) 1374-1380
21. Feng Y.M., Chen Q., Zhou J., Chen J., and Zeng H.S. Effects of leptin on the expression of tumor necrosis factor-alpha in RAW264.7 cells. Chin J Clin Rehabil 10 (2006) 181-184
22. Cheung A.T., Ree D., Kolls J.K., Fuselier J., Coy D.H., and Bryer-Ash M. An in vivo model for elucidation of the mechanism of tumor necrosis factor-alpha (TNF-alpha)-induced insulin resistance: evidence for differential regulation of insulin signaling by TNF-alpha. Endocrinology 139 (1998) 4928-4935
23. Pyorala K. Relationship of glucose tolerance and plasma insulin to the incidence of coronary heart disease: results from two population studies in Finland. Diabetes Care 2 (1979) 131-141
24. Welborn T.A., and Wearne K. Coronary heart disease incidence and cardiovascular mortality in Busselton with reference to glucose and insulin concentrations. Diabetes Care 2 (1979) 154-160
25. Ducimentiere P., Eschwege E., Papoz L., Richard J.L., Claude J.R., and Rosselin G. Relationship of plasma insulin level to the incidence of myocardial infarction and coronary heart disease. Diabetologia 19 (1980) 205-210
26. Fontbonne A., Charles M.A., Thibult N., et al. Hyperinsulinemia as a predictor of coronary heart disease mortality in a healthy population: the Paris Prospective Study, 15-year follow-up. Diabetologia 34 (1991) 356-361
27. Despres J.P., Lamarche B., Mauriege P., et al. Hyperinsulinemia as an independent risk factor for ischemic heart disease. N Engl J Med 334 (1996) 952-957
28. onkers I.J., Mohrschladt M.F., Westendorp R.G., van der Laarse A., and Smelt A.H. Severe hypertriglyceridemia with insulin resistance is associated with systemic inflammation: reversal with bezafibrate therapy in a randomized controlled trial. Am J Med 112 (2002) 275-280
29. Orel M., Lichnovska R., Gwozdziewiczova S., et al. Gender differences in tumor necrosis factor alpha and leptin secretion from subcutaneous and visceral fat tissue. Physiol Res 53 (2004) 501-505
30. Von-Eyben F.E., Mouritsen E., Holm J., et al. Intra-abdominal obesity and metabolic risk factors: a study of young adults. Int J Obes Relat Metab Disord 27 (2003) 941-949
31. Wong S., Janssen I., and Ross R. Abdominal adipose tissue distribution and metabolic risk. Sports Med 33 (2003) 709-726
32. Sada K.E., Yamasaki Y., Maruyama M., et al. Altered levels of adipocytokines in association with insulin resistance in patients with systemic lupus erythematosus. J Rheumatol 33 (2006) 1545-1552